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CLINICAL REVIEW
Mortality in COPD: Inevitable or Preventable?
Insights from the Cardiovascular Arena
David Halpin (David.Halpin@rdeft.nhs.uk)
ABSTRACT
Mortality due to chronic obstructive pulmonary disease continues to rise, whereas mortality
rates related to cardiovascular disease appear to be slowing, or even declining. This is due
at least in part to more widespread use of preventative therapies that have been shown to re-
duce cardiovascular mortality, raising the question of whether appropriate use of therapies for
chronic obstructive pulmonary disease which potentially reduce mortality could have a sim-
ilar impact. This article discusses approaches used successfully in managing heart disease
and considers whether these can be applied to chronic obstructive pulmonary disease and
whether a better understanding of the strongest predictors of mortality in chronic obstructive
pulmonary disease is needed. It reviews the role of inhaled corticosteroids, both alone and in
combination with long-acting β2-agonists, in individuals with chronic obstructive pulmonary
disease, including the role of combination therapy with inhaled corticosteroids/long-acting β2-
agonists (budesonide/formoterol or salmeterol/ﬂuticasone propionate) in decreasing exacerba-
tions and improving health status, potentially providing survival beneﬁts in chronic obstructive
pulmonary disease. This review also discusses the potential impact of treatments indicated for
cardiovascular disease on chronic obstructive pulmonary disease and possible links between
the two diseases.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is deﬁned
by the Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) 2006 Guidelines as “ap reventable and treatable
disease with some signiﬁcant extrapulmonary effects that may
contribute to the severity in individual patients. Its pulmonary
component is characterized by airﬂow limitation that is not
fully reversible. The airﬂow limitation is usually progressive
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and associated with an abnormal inﬂammatory response of the
lung to noxious particles or gases” (1). COPD is usually caused
by cumulative exposure to tobacco smoke, which in the western
world is the dominant factor in up to 90% of cases, but occupa-
tional dusts and chemicals, and indoor or outdoor air pollution
may also play a role (1). In addition to the pulmonary manifes-
tations of the disease, COPD is also associated with systemic
effects that may lead to osteoporosis, skeletal muscle dysfunc-
tion and cachexia (1, 2).
COPD frequently coexists with other chronic conditions and
the presence of these co-morbidities adversely affects outcome.
Some of the co-morbidities share a common aetiology with
COPD and in the past it has been assumed that this explained
theircoexistence.Recently,however,ithasbeenrecognizedthat
additionalsystemiceffectsofCOPDincludeanincreasedriskof
myocardial infarction (MI) and other cardiovascular manifesta-
tions, most of which are likely to be associated with an ongoing
low-grade systemic inﬂammation (2).
COPDisacommondisease.In2002,theprevalenceofCOPD
according to the Global Burden of Disease Study was estimated
to be 11.6/1,000 in men and 8.77/1,000 in women (3), although
COPDprevalenceishigherinolderadultsandincountrieswhere
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ous reports indicate that mortality due to COPD continues to
increase,withtheglobalproportionofdeathsattributedtoCOPD
predicted to increase by approximately 65% between 2002 and
2030 (1, 4). In comparison, mortality rates related to cardiovas-
cular disease (CVD) appear to be slowing, or even declining, in
Western populations (4–7). This is due, at least in part, to more
widespread use of therapies for CVD that have been shown to
reduce mortality. One of the main contributing factors is in-
creased uptake of the 3-hydroxy-3-methyl-glutaryl-coenzyme
A(HMG-CoA)reductaseinhibitors,orstatins,forthetreatment
of dyslipidaemia and atherosclerotic disease (8–11).
Increasedawarenessandimplementationoftreatmentguide-
lines may also contribute to reductions in CVD mortality, with
physicians and patients becoming better educated about treat-
ment goals and effective treatments, leading to increased up-
takeofstatinsandothercardiovascularmedications.Inaddition,
lifestyle modiﬁcation programmes promoting improved aware-
ness and better control of risk factors for CVD, such as reduc-
tions in smoking, blood pressure and cholesterol, have proved
effective and may help to explain the slowing of CVD mortality
observed in Western populations (6, 7).
This article considers the extent to which these insights
from managing heart disease may be applicable to COPD, and
whether currently available treatments for COPD can have a
signiﬁcant impact on mortality. For example, smoking cessa-
tion and long-term oxygen therapy (where indicated) have been
shown to reduce mortality in randomized clinical studies (12–
14). In addition, this review discusses the relationship between
COPD mortality and key risk factors including airﬂow obstruc-
tion, the BODE index (incorporating body mass index, airﬂow
obstruction, dyspnoea and exercise capacity), impaired health
status, increased exacerbations, declining lung function and co-
morbidities where systemic inﬂammation may provide the link
between COPD and CVD (2, 15–18).
Studies have indicated the potential beneﬁts of COPD treat-
ments such as the inhaled corticosteroids (ICS), with or without
long-acting β2-agonists (LABAs), on mortality in patients with
COPD (19–32). The article also discusses the role of combina-
tion therapy with ICS/LABA (budesonide/formoterol or salme-
terol/ﬂuticasone propionate) in reducing exacerbations and im-
proving health status, and their potential for decreasing COPD
mortality. These beneﬁts are examined from a similar perspec-
tive to that used to assess treatment outcomes in CVD (25–32).
Trends in COPD and CVD mortality
COPD is widely acknowledged as a major, and increasing,
cause of mortality and morbidity across the globe. It is currently
thefourthleadingcauseofdeathworldwide(1).Causesofdeath
in COPD patients include COPD-related deaths as well as other
causes,forexample,CVDandlungcancer(33,34).COPDdeath
rates increase with age, and are higher in males than in females
(35). Globally, COPD accounted for 4.8% of deaths in 2002, a
ﬁgure that the World Health Organization (WHO) predicts will
increaseto7.9%by2030(4).COPDalsohasasigniﬁcantimpact
on quality of life, as evidenced by WHO ﬁgures estimating a
change in ranking for COPD in terms of the proportion of total
disability-adjusted life-years lost, from rank eleventh in 2002 to
rank fourth in 2030 (4).
Furthermore, there is evidence that the burden of COPD may
be underestimated. Firstly, the disease is usually not diagnosed
untilitisclinicallyapparentandmoderatelyadvanced,whilethe
existence of varying deﬁnitions of COPD have made it difﬁcult
to quantify the burden of the disease (36). Secondly, mortality
data may substantially underestimate COPD as a cause of death
by citing COPD as a contributory, rather than an underlying,
cause of death, or by not citing COPD at all on death certiﬁ-
cates. For example, in a study analysing the epidemiology of
deaths in England and Wales, only 60% of deaths where ob-
structive lung disease (COPD or asthma) was mentioned on the
death certiﬁcate were attributed to COPD/asthma as the under-
lyingcauseofdeath(34).Incontrast,94%ofdeathsmentioning
MI on the death certiﬁcate were attributed to MI as the under-
lying cause of death (34). Similarly, data from Denmark and
the USA, respectively, suggest that COPD is under-reported on
death certiﬁcates (37) and that mortality related to obstructive
lung disease is underestimated in studies that look only at the
underlying cause of death (38). In these studies, the principal
causes of mortality in COPD included CVD and lung cancer
(37, 38).
There is evidence that COPD mortality may be worsening
relative to mortality due to CVD, MI or stroke. For example,
although WHO estimates suggest that ischaemic heart disease
and stroke will remain ranked ﬁrst and second leading causes
of death worldwide in 2030, there is also evidence that the
increase in CVD mortality is slowing substantially relative to
COPD (4).
In fact, globally, the proportion of deaths attributed to COPD
are predicted to increase by approximately 65% between 2002
and 2030, compared with less than 10% increases for both is-
chaemic heart disease and stroke (4). Furthermore, U.S. data
examining trends in the leading causes of death (1) between
1970 and 2002 indicate a decline in mortality due to CVD, with
age-standardized death rates decreasing by 52% for heart dis-
ease and 63% for stroke over this time period (Figure 1) (5).
In contrast, age-standardized death rates due to COPD doubled
between 1970 and 2002 (5). In the UK, deaths due to coronary
heart disease (CHD) are also declining, with a 54% reduction in
CHD mortality rates recorded between 1981 and 2000 (6).
These trends in mortality may be explained by a number of
factors. For example, almost 60% of the observed decrease in
CHD deaths in the UK has been attributed to reduction in major
riskfactors,particularlysmoking,whileover40%wasattributed
to the combined effects of adoption of modern cardiology treat-
ments, including statins (6, 7). Of note, uptake of statins for
the treatment of atherosclerosis has increased markedly over
the past decade. This was illustrated in a questionnaire-based
study conducted in the UK in 1998–2000 and 2003 in individ-
uals with MI or angina (8). The study reported an almost dou-
bling in statin usage during this time period (Figure 2) (8). In
addition, increased awareness and implementation of treatment
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guidelines may also contribute to reductions in CVD mortality,
with physicians and patients becoming better educated about
treatment goals and effective treatments (39). Development of
management guidelines for CVD has primarily been driven by
ﬁndings from large clinical trials based on robust clinical out-
comes (including mortality), resulting in increased prescribing
in clinical practice (40).
In comparison with CHD, COPD is under-diagnosed and
under-treated (36, 41). This may, at least in part, be due to
the complexity and multicomponent nature of COPD, which
comprises structural and functional changes occurring both in-
side and outside the lung. These include airﬂow limitation,
airway inﬂammation, mucociliary dysfunction and structural
changes in the airways and lung parenchyma, as well as sys-
temiceffects,suchasskeletalmuscledysfunction,osteoporosis,
cachexia, cardiovascular and nervous system abnormalities and
chronic, low-grade inﬂammation (1, 2, 15, 18, 42–44). In addi-
tion, many individuals with COPD are not formally diagnosed
because they consider breathlessness and limited exercise toler-
ance to be signs of ageing and regard their smoker’s cough as
normal(41).Thereisalsoevidencethat,incontrastwithasthma,
COPD is under-treated by primary care physicians, particularly
in the early stages of the disease (45). There is therefore a need
for better understanding of the strongest predictors of mortal-
ity in COPD and the potential impact of therapies on COPD
mortality.
Predicting COPD mortality
There is considerable debate regarding the strongest predic-
torsofmortalityinCOPD.Keypredictorsincludeadvancedage
(46–49), smoking status (48), low forced expiratory volume in
Figure 2. Prevalence of statin use for secondary prevention in patients with myocardial infarction or angina (8).
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1 second (FEV1) (47, 48, 50), peak expiratory ﬂow (50), low
arterial partial pressure of oxygen (PaO2) (51, 52), low body
mass index (52, 53) and reduced exercise capacity (49, 54). The
BODE index – a composite index reﬂecting the multicompo-
nent nature of COPD – has also proved to be a good predictor
of mortality as it incorporates systemic as well as pulmonary
characteristics of COPD (49, 55, 56).
Reduced health status/health-related quality of life is also
gaining increasing recognition as a predictor of mortality. In-
struments used to measure health status in COPD include the
Medical Outcomes Study Short Form 36-item (SF-36) Health
Survey, the St George’s Respiratory Questionnaire (SGRQ),
the Breathing Problems Questionnaire and the Seattle Obstruc-
tive Lung Disease Questionnaire. Health status measured using
these questionnaires has been shown to predict mortality and, in
some cases, hospitalization in COPD (54, 57–62). For example,
the SGRQ provides an effective measure of health-related qual-
ity of life during acute exacerbations of COPD (63) and reliably
predictsmortalityinindividualswithCOPD(32,54,57–59,61).
Depression and disability also predict mortality in patients dis-
charged from hospital following acute exacerbations of COPD
(61).
There is growing interest in the impact of exacerbations
on mortality and morbidity in COPD. Severe exacerbations
of COPD have been shown to be associated with a worse
prognosis, and mortality increases with the frequency of
exacerbations (64). Exacerbations of COPD severe enough
to require hospitalization have a signiﬁcantly greater ef-
fect on mortality than those which can be managed in the
community.
The magnitude of mortality following an exacerbation is not
widely known. Data from several studies show that mortality
at 12 months following hospitalization for an exacerbation of
COPD is between 20% and 40%. This is much worse than the
mortality observed following hospital admission with an acute
MI, whether or not patients received acute reperfusion therapy
(Figure 3) (32, 64–70). In addition, COPD exacerbations impair
health-related quality of life and patient well-being, as well as
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the need for hospital admissions (71–73). Given evidence that
patients under-report exacerbations (71, 74), the extent of their
effects on mortality and morbidity may be greater than current
ﬁgures indicate.
In contrast, CVD risk factors are more clearly deﬁned and
more easily measurable. Epidemiological evidence has increas-
ingly been used as a rationale for clinical trials in CVD, as
reviewed in Ramsey et al. (40). This reﬂects recognition of the
important role that managing risk factors plays in the clinical
managementofthedisease.Severalkeyriskfactorshavebeendi-
rectly linked to outcomes and epidemiological data have shown
the importance of speciﬁc clusters of cardiovascular risk factors
in certain individuals. For example, the INTERHEART study
demonstrated that the nine traditional risk factors for CVD ex-
plained over 90% of the attributable population risk for MI (75).
Cardiovascular risk scoring systems such as the Framingham
risk calculator have been developed to identify individuals at
particularly high risk of atherosclerosis and thus improve deci-
sionmakingaboutinterventionsforprimarypreventionofCVD.
Biomarkers such as cardiac troponins are also available to
stratify risk and direct subsequent management of patients with
acute events such as unstable angina or a suspected MI (76, 77).
Incorporation of these ﬁndings into CVD treatment guidelines
(76,78,79)hasfacilitatedearlydiagnosisandallowsphysicians
to optimize treatment.
Key biomarkers for CVD may also be related to exacerba-
tions in COPD patients, for example, troponins are reported to
be elevated in COPD patients suffering from acute exacerba-
tions (80). However, despite increased interest in the associa-
tion of inﬂammatory biomarkers (e.g., tumour necrosis factor
alpha,leukotrieneB4,interleukin-8andbiomarkersofoxidative
stress) with exacerbations of COPD (1, 81), they do not provide
information that can be used to stratify the risk of mortality or
identify subgroups of patients requiring different management
strategies.
Impact of therapies on COPD mortality
ThegoalsofeffectiveCOPDmanagementincludeimproving
health status, preventing and treating exacerbations and reduc-
ing mortality (1). Control of risk factors, in particular the im-
plementation of smoking cessation programmes, should have a
signiﬁcant impact on COPD prevalence, leading ultimately to a
reduction in COPD mortality, as in the cardiovascular arena. As
well as reducing the future prevalence of the disease, smoking
cessation has been shown to reduce mortality in a clinical trial
setting (12) and is the single most effective (and cost-effective)
intervention to reduce the risk of developing COPD and stop its
progression (1). However, the immediate beneﬁts of stopping
smoking in COPD may be less than those seen in CVD and pa-
tients with COPD may have particular difﬁculty quitting as it
appears that smoking cessation strategies are often ineffective
in individuals with COPD (82, 83).
COPD mortality is still continuing to increase and there
is a need for pharmacological interventions that can reduce
mortality in patients with established disease. Current pharma-
cologicaloptionsforthetreatmentofCOPDincludeshort-acting
β2-agonists (SABAs; e.g., salbutamol and terbutaline), LABAs
(e.g., formoterol and salmeterol), short-acting and long-acting
anticholinergics (e.g., ipratropium bromide and tiotropium bro-
mide, respectively), theophylline, ICS (e.g., beclomethasone
dipropionate, budesonide and ﬂuticasone propionate), ﬁxed-
dose combinations of ICS/LABA and SABA/anticholinergic,
and systemic glucocorticosteroids. Historically, the focus of
these treatments has been on improving physiological measures
of lung function and providing symptom relief, but there is now
increasing interest in their impact on health status and their pos-
sible effects on reducing premature death. Of these treatments
the most promising regarding reductions in mortality appear to
be ICS, particularly in combination with a LABA.
ICS and their impact on exacerbations, health status and
mortality. Until recently there was a lack of randomized clini-
caltrialdataontheeffectsofICSonmortalityandtheonlyinfor-
mation available came from several retrospective/observational
studies, which suggested that ICS may have a beneﬁcial effect
on mortality in patients with COPD.
Several population-based cohort studies evaluating longitu-
dinal healthcare databases in Canada (19–21, 24, 84) have sug-
gested that receiving ICS following hospitalization for COPD
reduces the risk of death, but these studies have been criticized
on the grounds that they include an “immortal time bias” which
favours patients prescribed ICS (85).
The Canadian database study (19) is susceptible to immor-
tal time bias as patients were classiﬁed as receiving ICS if they
were dispensed a prescription within 90 days of discharge from
hospital. Thus, in order to be eligible to enter the ICS group
they must have survived at least as long as the interval from
hospital discharge (which was deﬁned as the cohort entry time)
until ICS were prescribed and during this time they were effec-
tively immortal as they could not die, whereas patients not in
the ICS group could die at any time from cohort entry. Whether
or not this time period affected the analysis is not known, but
the potential for the bias to inﬂuence the results must be con-
sidered. It has also been proposed that immortal time bias may
also affect the hierarchical cohort design used in the study by
Soriano and colleagues (20). In this case the criticism centres
aroundtheexclusionofimmortaltimeinthenon-ICSgroupand
the impact this may have had on the survival analysis. In this
analysis patients who were not receiving ICS at cohort entry but
who received them at some point during the follow-up period
wereexcludedfromthefollow-upanalysis.Ithasbeensuggested
that excluding these patients from the follow-up analysis led the
authors to ignore the immortal time these patients experienced
prior to receiving ICS and led to a ﬂawed conclusion about the
effect of ICS on mortality (86). On the other hand, it seems very
reasonabletobasetheconclusionsonanalysisofsurvivalintwo
cohorts, one of which received ICS at cohort entry and another
in which patients did not receive ICS throughout the follow-up
period.
The epidemiological data on survival beneﬁts of ICS is sup-
ported by observational data in very severe COPD patients
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oxygen therapy, compared to those who did not use ICS
concomitantly (22). However, it is important to note that
these are observational data, that patients were not ran-
domized to steroid therapy, and that little or no informa-
tion is available to assess baseline risk in the treatment
groups.
FurtherinsightintotheimpactofICSonoutcomesisprovided
by data from prospective randomized clinical trials, including
data from pooled trials. For example, the Inhaled Steroids in
Obstructive Lung Disease (ISOLDE) trial was a double-blind,
placebo-controlled study investigating the impact of ICS in 751
patients with moderate to severe COPD (87). In ISOLDE, ﬂuti-
casonepropionatesigniﬁcantlyreducedtherateofexacerbations
and slowed the rate of decline of health-related quality of life
(87–89) and a post hoc analysis of the study showed a non-
signiﬁcant trend towards improved survival in patients from the
ﬂuticasone propionate arm (P= 0.069) (90). Although signif-
icance was not reached, this may be due to the small size of
the study population and the limited follow-up interval. Sim-
ilar ﬁndings come from a systematic review of randomized
placebo-controlled ICS trials in COPD patients by Alsaeedi and
colleagues (91): the summary relative risk of the trials was con-
sistent with a small survival beneﬁt, but the effect was not sta-
tistically signiﬁcant (91).
Sin and colleagues carried out a pooled analysis of intention-
to-treat data from seven large, long-term randomized trials, col-
lectively involving more than 5,000 patients (23). This pooled
analysis, known as the Inhaled Steroid Effects Evaluation in
COPD (ISEEC) study, found that ICS reduced all-cause mor-
tality by over 25% relative to placebo over a mean follow-up
of 26 months (23). These beneﬁcial effects appeared to be most
pronounced in women and former smokers (23). Interestingly,
in a retrospective analysis of the 3-year EUROSCOP study of
patients with mild to moderate COPD, which was included in
the ISEEC pooled analysis, the incidence of pre-deﬁned car-
dioischaemic events was signiﬁcantly lower in the budesonide
armcomparedwithplacebo(92).However,theauthorsnotethat
additionalstudiesarerequiredtodeterminewhetherthesurvival
beneﬁts persist beyond 2–3 years, and to evaluate long-term ad-
verse events (23).
Overall, there is a large body of evidence which suggests
that ICS provide a survival beneﬁt in COPD. However, data
from the ﬂuticasone arm in the TOwards a Revolution in COPD
Health (TORCH) study, which investigated the impact of sal-
meterol/ﬂuticasone propionate in a single inhaler on mortality
and SGRQ over 3 years in over 6,000 patients with moderate
to severe COPD, did not show a reduction in all-cause mortal-
ity at 3 years versus placebo (93). The reasons why this result
differs from the observational studies and post hoc analyses are
not clear, particularly as ﬂuticasone propianate reduced the rate
of exacerbations.
Although more episodes of pneumonia were reported as ad-
verse events in patients treated with ICS there was no difference
in the incidence of fatal pneumonia and it may simply be that
when complete follow-up is available, biases are eliminated so
that the null hypothesis that ICS reduce mortality is disproved.
Further studies are needed to clarify this.
Long-acting bronchodilator use in patients with COPD.
LABAs have an important role in managing the symptoms of
COPD, with side effects generally considered to be predictable
anddose-dependent.Arecentmeta-analysisofrandomizedcon-
trolledtrialsevaluatingtheuseofLABAsoveraperiodofatleast
3 months has suggested an increased rate of respiratory deaths
with LABAs compared with placebo (94). However, recent ran-
domized studies have shown that LABAs are well tolerated in
patients with COPD and have a good safety proﬁle (95–97).
Similar concerns have been expressed with regard to LABA
use in adults with asthma; however, it is clear that when used
appropriately,i.e.,incombinationwithICS,thereisnoevidence
of a safety risk (98, 99). Any observed adverse outcomes asso-
ciated with LABA monotherapy were caused by “masking of
inﬂammation” rather than a toxic effect of the drugs, and such
concerns are of less relevance in COPD where the pattern of
inﬂammation and the effects of ICS on this are different.
TherecentprospectivestudybyGudmundssonetal.indicated
an improvement in survival, in patients taking LABAs alone,
among those who had been hospitalized for acute exacerbations
of COPD, as described previously (32). More importantly, the
TORCHstudyalsosupportedthesafetyofLABAsinindividuals
with COPD, and showed a trend towards increased survival for
patients treated with salmeterol alone compared with placebo
(hazard ratio 0.879, 95% CI 0.729–1.061) and no increase in
adverse events (93).
The long-acting muscarinic antagonist (LAMA) tiotropium
also provides effective symptom control and reduces exacerba-
tionfrequencyinpatientswithCOPD(100).Aposthocanalysis
of 1-year data suggests that it may reduce the rate of decline of
FEV1 (101), and, if this is a real effect, LAMAs may have an
effect on mortality. The results of the UPLIFT trial (102) should
help shed some light on this when they are published.
The beneﬁts of adding ICS to LABAs. Combined therapy
with ICS/LABA improves health status and reduces the fre-
quencyofexacerbations,asdemonstratedbytwo12-monthran-
domizedstudiesevaluatingtheeffectsofbudesonide/formoterol
in a single inhaler in individuals with COPD (29, 30). In the
ﬁrst study (Szafranski et al.), budesonide/formoterol reduced
the mean number of severe exacerbations (deﬁned as requir-
ing oral corticosteroids and/or antibiotics and/or hospitalization
due to respiratory symptoms) by 24% versus placebo and 23%
versus formoterol in 812 patients with COPD and signiﬁcantly
improved health-related quality of life versus placebo (29).
In the second study (Calverley et al.), of 1,022 patients with
COPD, those taking budesonide/formoterol had a prolonged
timetoﬁrstexacerbationrequiringmedicalintervention(deﬁned
asrequiringoralcorticosteroidsand/orantibioticsorhospitaliza-
tion), fewer exacerbations requiring medical intervention and a
clinically relevant improvement in health status (measured with
the SGRQ) compared with those on placebo (30).
Similarly, in the TRial of Inhaled STeroids ANd long-
acting beta-agonists (TRISTAN) study, use of salme-
terol/ﬂuticasone propionate in a single inhaler reduced the
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ticosteroids and/or antibiotics) in individuals with COPD
(103). These results have also been conﬁrmed in the
TORCH 3-year outcomes study, as described in more detail
next (93).
Data from number needed to treat (NNT) analysis also
demonstrate the beneﬁcial effects of ICS/LABA in prevent-
ing severe COPD exacerbations (31). NNT analysis is a useful
methodbecauseitallowsphysicianstoeasilyquantifythebene-
ﬁtsofalternativetreatmentoptionsondiseaseoutcomesinterms
of the number of patients who need to be treated in order to see
a particular outcome (31, 104, 105). Using data from the trials
mentioned earlier (29, 30), NNT analysis showed that 2.1–2.4
patients would need to be treated with budesonide/formoterol in
a single inhaler compared with formoterol alone (or placebo) in
ordertopreventoneexacerbationrequiringmedicalintervention
in 1 year (31). In other words, treating 100 patients with severe
to very severe COPD with budesonide/formoterol versus for-
moterol alone (or placebo) would prevent 42–47 exacerbations
requiring medical intervention during 1 year of treatment (31).
In the recent TORCH study, the NNT for salmeterol/ﬂuticasone
propionate in reducing exacerbations was 8.3 versus salmeterol
and 3.6 versus placebo, as calculated from the annualized exac-
erbation rates (106).
Using data from the TRISTAN study, the NNT for the pre-
vention of exacerbations by salmeterol/ﬂuticasone propionate
in a single inhaler over 1 year in a similar patient popula-
tion was of similar magnitude (3.0 versus placebo). In a sep-
arate trial, the VIVACE study, which compared the impact
of salmeterol/ﬂuticasone propionate and salmeterol on exac-
erbations in individuals with severe COPD, the NNT to pre-
vent one moderate/severe exacerbation per year with salme-
terol/ﬂuticasone propionate was 2.08 versus salmeterol alone
(107).
As is the case for ICS, until recently there was virtu-
ally no published data from prospective studies on the impact
of ICS/LABA on survival in patients with COPD. However,
other data suggest that combination therapy may have an ef-
fect on mortality, for example, retrospective data suggest that
ICS/LABA may improve survival versus either ICS or LABA
alone (20, 25, 26). In an observational study analysing data
from the UK General Practice Research Database, COPD pa-
tients treated with ﬂuticasone propionate and salmeterol (n =
1,045)werecomparedwiththosewhoregularlyusedotherbron-
chodilators but not ICS or LABAs (n = 3,620) (20). After 3
years, survival was signiﬁcantly greater in ﬂuticasone propi-
onate and/or salmeterol users versus the reference group, with
the highest survival advantage found in users of combined sal-
meterol/ﬂuticasone propionate (20).
Mortalitydecreasedasthenumberofprescriptionsofﬂutica-
sonepropionateand/orsalmeterolincreased(20).Aseparateret-
rospective cohort analysis of the UK General Practice Research
Database compared rehospitalization for a COPD-related con-
dition or death within a year of ﬁrst hospitalization in patients
prescribed ICS and/or LABA (n = 3,636) versus reference pa-
tients, who were on SABA only (n = 627) (25).
Use of ICS with or without LABAs was associated with a
reduction in rehospitalization or death in COPD patients, with
a 41% risk reduction in users of ICS/LABA (P< 0.05), 16%
reduction in ICS users (P < 0.05) and 10% reduction in LABA
users (nonsigniﬁcant) versus the reference group (25). In an-
other retrospective cohort study, this time of two U.S. managed
care organizations, COPD patients who used ICS, either alone
or in combination with LABAs, were again shown to have sub-
stantially improved survival, even after adjustment for asthma
and other confounding factors (26).
Data from a prospective study (Gudmundsson et al.) have
recently conﬁrmed the ﬁndings of these retrospective analyses,
showing an association between ICS and LABA treatment and
reduced mortality (32). Four-hundred and sixteen patients with
COPD who had been hospitalized for an acute exacerbation
were followed for 2 years (32). During the follow-up, 29% of
the patients died, with diabetes, advanced age, low FEV1 and
lowerhealthstatusassociatedwithanincreasedriskofmortality
(32).PatientstreatedwithICSand/orLABAshadalowerriskof
death compared with patients taking neither of these treatments
(32); however, patients were not randomized to treatment and
thus considerable potential for bias exists.
Arecentpooledanalysisoftwolargerandomizedstudieshas
further investigated the impact of adding ICS to bronchodila-
tors on COPD mortality (27). Mortality and baseline data were
pooled from the Szafranski et al. and Calverley et al. studies
(29, 30), together involving more than 1,800 individuals with
COPD who were treated with budesonide/formoterol (in a sin-
gle inhaler) or budesonide versus formoterol or placebo over 1
year. The pooled data indicated that budesonide, either alone or
in combination with formoterol, signiﬁcantly reduces the risk
of death from any cause at 1 year compared with formoterol
or placebo maintenance therapy (P= 0.039; Figure 4) (27). Ef-
fects of budesonide on survival were apparent in all patients,
irrespective of age, sex or lung function (FEV1) (27).
All these analyses suffer from the same problems as the ob-
servational studies of ICS discussed above. The TORCH study
was designedtoprovideprospectivedataonthisquestionina3-
yearrandomizedclinicaltrial.Thisstudydifferedfromprevious
studies by specifying all-cause mortality as a primary endpoint
andincludingrigorousmethodstoestablishwhetherallpatients,
including those that had dropped out, were alive or dead at the
end of 3 years (93, 108). Results from TORCH reported that
whilst salmeterol/ﬂuticasone propionate decreased the risk of
mortality over the 3 years by 17.5% compared with placebo,
the reduction did not quite achieve statistical signiﬁcance (P=
0.052) (93).
Calverley and colleagues plausibly suggest the study failed
to reach statistical signiﬁcance because it may have been under-
powered (93). TORCH was designed to have 90% power to de-
tectaneffectof4.3percentagepointsonoverallmortality,while
the ﬁnal results showed a reduction of 2.6 percentage points. A
prespeciﬁed secondary analysis (Cox proportional-hazards test-
ing) showed a signiﬁcant reduction in the hazard ratio to 0.811
(95% CI 0.670–0.982; P= 0.03), suggesting that the effect on
mortality is genuine. The results of the study are also likely to
COPD: Journal of Chronic Obstructive Pulmonary Disease June 2008 193Figure 4. Effect of budesonide-containing therapy (budesonide/formoterol or budesonide) versus reference therapy (formoterol or placebo) on
mortality (27).
Figure 5. Survival beneﬁt observed with ICS in COPD compared with that of the statins in coronary heart disease (9, 23). ICS = inhaled
corticosteroids, ISEEC = Inhaled Steroid Effects Evaluation in COPD, 4S = Scandinavian Simvastatin Survival Study.
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treatment on mortality as a result of the inherent limitations as-
sociated with a 3-year study which includes a placebo arm. This
may have led to bias due to early and differentiated drop-out of
patients (109). For example, an early and larger drop-out rate
in the placebo group may generate a healthy survivor bias for
those staying on in the study. Additionally, some of the patients
who have dropped out of the placebo arm may subsequently
havereceivedactivetreatmentfromtheirclinicians.Thus,when
analysed on an intention-to-treat basis, such patients would lead
to an underestimation of the beneﬁts of combination therapy.
TORCHalsodemonstratedthatsalmeterol/ﬂuticasonepropi-
onate improved lung function and health status (measured using
theSGRQ)(93).Salmeterol/ﬂuticasonepropionatealsoreduced
moderate/severe exacerbations, with signiﬁcantly superior ef-
fects observed compared with placebo, ﬂuticasone propionate
alone and salmeterol alone over 3 years (93). This reduction
in exacerbations was of similar magnitude to that reported in
the TRISTAN study (103). Data from TORCH also indicated
that salmeterol/ﬂuticasone propionate was well tolerated, with
af avourable long-term beneﬁt/risk ratio compared with placebo
(110).
An unexpected but statistically signiﬁcant increase in the in-
cidence of non-fatal pneumonia was observed in patients taking
salmeterol/ﬂuticasone propionate compared with placebo in the
TORCH study (3-year duration) (93, 110). This concords with
datafromtheVIVACEstudy(2-yearduration),whichshowedan
increase in pneumonia in patients taking salmeterol/ﬂuticasone
propionate versus salmeterol alone (107). Similar ﬁndings were
not seen in the Calverley and Szafranski studies of budes-
onide/formoterol (1-year duration): pneumonia incidence was
less than 5% and was similar between the budesonide and non-
budesonide groups (29, 30).
It is not clear why there is a discrepancy between the results
of the TORCH study (93) and previous studies (20, 23, 25–27,
32). One reason may be that the observed differences are due to
variationsinpatientpopulations.Anotheristhatcompleteinfor-
mation was available on vital status in all randomized patients
intheTORCHstudy,whereasitwasonlyavailableinthosewho
completed the previous studies and thus these may have been
inﬂuenced by a healthy survivor effect. Additional randomized,
controlled clinical trials are required to investigate further the
effects of ICS/LABA on mortality.
Additionalbeneﬁtsofstatins. Interestingly,statinsmaypro-
vide additional beneﬁts in patients with COPD. Retrospective
data demonstrate that, in patients who had been hospitalized
for COPD exacerbations, treatment with statins or ICS post-
discharge led to signiﬁcant reductions in mortality, with the
greatest beneﬁts reported in patients taking both statins and
ICS (111, 112). In another retrospective study, both cardio-
vascular and pulmonary outcomes were reduced in COPD pa-
tients taking statins, angiotensin-converting enzyme inhibitors
and angiotensin receptor blockers (113). Use of these agents
was associated with reduction in COPD hospitalization and to-
tal mortality, not only in the high cardiovascular risk cohort but
alsointhelowcardiovascularriskcohort,whilethecombination
also reduced MI in the high cardiovascular risk cohort (113). A
further retrospective study conducted by Younis and colleagues
reported a 35% decline (P= 0.02) in the rate of hospitalization
and emergency room treatment among COPD patients (114).
Randomized clinical trials are required to conﬁrm these obser-
vations and to investigate the mechanism by which these agents
may exert their effects in individuals with COPD.
Limitations of randomized controlled trials, observational
studies and post hoc analyses. When considering the studies
discussed above it is important to note that, with the exception
of the TORCH study, the studies were not designed to assess
mortality rates. Patients in the database studies were not ran-
domized to the different treatment arms and in both these and
theposthocanalyses,intention-to-treatanalysesarenotpossible
in most cases, as patients are not followed after study discontin-
uation or biases such as immortal time bias are introduced.
In most studies entry criteria excluded patients at higher risk
of death, e.g., those with concomitant CVD and recent exacer-
bations, and most studies were underpowered as death was an
uncommon event. All studies were of relatively short duration
and signiﬁcant numbers of patients withdrew from the random-
izedcontrolledtrials.Nevertheless,takentogether,thesestudies
provideacompellingcasethatpharmacotherapycanaffectmor-
tality in COPD.
Looking forward: what can we learn from CVD? In tandem
withmoreeffectivetreatmentsforacuteMI,bettercontrolofrisk
factors for CVD, notably using statins, has had a marked impact
in decreasing mortality due to CVD. Large-scale clinical trials,
includingtheScandinavianSimvastatinSurvivalStudy(4S),the
West of Scotland Coronary Prevention Study (WOSCOPS) and
the Aggressive Lipid-Lowering Initiation Abates New Cardiac
Events (ALLIANCE) study (9–11), have demonstrated the ben-
eﬁcial effects of statin therapy on survival, and key ﬁndings
from these studies have been incorporated into CVD treatment
guidelines. Increased awareness and implementation of guide-
lines has resulted in physicians and patients becoming better
educated about treatment goals and effective treatments, lead-
ing to increased prescribing of statins and other cardiovascular
medications that improve survival. This in turn has contributed
to the deceleration, or even decline, in CVD mortality rates ob-
served in Western populations (4–8).
What can we do to decrease deaths due to COPD? Once
viewed as an irreversible condition, COPD is now considered a
treatable disease. As with CVD, improved control of risk fac-
tors for COPD (i.e., smoking cessation) will, over time, have a
major impact on mortality. Pulmonary rehabilitation and long-
term oxygen therapy in hypoxic patients can improve survival,
whilelungvolumereductionsurgeryisalsobeneﬁcialinselected
cases. However, for many patients with established disease the
major impact on mortality is likely to come from pharmacolog-
ical interventions which mirror the beneﬁts of statins in heart
disease. Much effort has been put into developing such treat-
ments,butwemayalreadyhavedrugsthatcanreducemortality.
As discussed before, the use of ICS, either alone or in com-
bination with LABAs, appears to have a beneﬁcial effect on
survival which may be comparable to the effects seen with the
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Drug class Trial NNT
Lipid-lowering drugs Meta-analysis (118) 69 for primary prevention of non-fatal MI or cardiovascular death
Aspirin European Stroke Prevention Study (119) 34 for secondary stroke prevention
ACE inhibitors HOPE Trial (120) 27 for cardiovascular events or death
Statins 4S Trial (121) 17 for cardiovascular events, 30 for death
Salmeterol/ﬂuticasone propionate GOAL Study (122) 10–20 for severe asthma exacerbation
Budesonide/formoterol Halpin et al. (31) 2.1–2.4 for COPD exacerbation requiring medical intervention
Salmeterol/ﬂuticasone propionate VIVACE Study (107) 2.08 for moderate/severe exacerbation
ACE = angiotensin-converting enzyme; 4S = Scandinavian Simvastatin Survival Study; HOPE = Heart Outcomes Prevention Evaluation;
GOAL = Gaining Optimal Asthma ControL.
statins. Figure 5 compares data from one of the key cholesterol-
lowering trials in patients with CHD, 4S, with ﬁndings of the
ISEEC study in patients with COPD (9, 23). Furthermore,
statins also have anti-inﬂammatory properties (115, 116), in
addition to their lipid-lowering properties, which may have a
beneﬁcial impact in COPD (112, 113, 117). Currently, statins
are only indicated in those suffering from hyperlipidaemia;
however, further research is needed to explore the impact of
statin therapy in COPD patients, and speciﬁcally, this research
should focus on the impact of statins alone as well as the ef-
fectsofstatinsgivenconcurrentlywithICS/LABAcombination
therapy.
NNTanalysisprovidesafurtherindicationofthefactthatwe
may have overlooked the efﬁcacy of the drugs we already have
available.TheimpactofICSonsurvivalinCOPDcomparesvery
favourablywithothercommonlyacceptedtreatmentsforchronic
diseases (28, 31). For example, using data from the Ontario
population-based cohort study described earlier (19), the NNT
for ICS in COPD has been calculated for survival (NNT = 27),
comparing favourably with the NNT for ICS in asthma (NNT =
72) and for the commonly used ﬁbrate, gemﬁbrozil, in coronary
arterydisease(NNT=1,000)(28).Notethattheseestimatesare
from studies with very different designs and which are, there-
fore,subjecttoanumberofsystematicbiases(28).Othersample
NNT values for preventative interventions are shown in Table 1.
Again, note that these data should be interpreted with caution
because of the limitations of comparing NNTs across different
drugs/diseases.Forthisreason,physiciansareencouragedtouse
NNT data in conjunction with other considerations when mak-
ingclinicaldecisions.Forexample,NNTvaluescanvarywidely
evenforthesamedrug/diseaseaccordingtofactorssuchasbase-
line disease severity and other differences in study populations
(31).Henceitisimportanttocompare‘likewithlike’withregard
to patient populations, study designs and outcome endpoints. In
addition, for some patients a non-fatal MI or stroke may be a
more signiﬁcant event than a COPD exacerbation, with greater
consequences for impact on future mortality and health status.
However,theimpactofaCOPDexacerbationhasoftenbeenun-
derestimated in the past, so these comparisons are still relevant
(31).
CONCLUSION
COPDisamajorcauseofdeathworldwide.Actionisneeded
toimproveunderstandingoffactorsthatcanbeincorporatedinto
clinical practice to identify patients at risk of dying from their
COPD and to increase the number of patients treated for COPD.
Increased use of therapies such as ICS, particularly combined
with LABAs, has shown promising effects in decreasing mor-
tality in patients with COPD, as well as reducing exacerbations
and improving health status. In concert with better control of
risk factors for COPD, in particular smoking, these therapies
may have the potential to help reduce death rates from COPD
and to improve the outlook for patients with COPD.
The concept of secondary prevention following an exacer-
bation needs to be introduced more widely. Patients who have
had an exacerbation should be offered treatment with combi-
nations of drugs which have been shown to reduce the risk of
future exacerbations (i.e., they should be prescribed combina-
tions of ICS, LABA and LAMA). In addition, COPD patients
should be encouraged to address lifestyle factors such as stop-
ping smoking and controlling weight and they should undertake
pulmonary rehabilitation when indicated. If used appropriately
these treatments may lead to reductions in COPD mortality,
mirroring the signiﬁcant slowing of CHD mortality seen over
the last few decades. Furthermore, combining COPD therapy
with other drugs such as statins may be beneﬁcial in targeting
systemic inﬂammation, an underlying characteristic common to
both COPD and CHD, offering the potential to further inﬂuence
disease progression.
We may already have the tools to improve survival in COPD,
but they are frequently underused and we must learn lessons
from the management of CVD and copy their success if we are
to make a real difference to patients.
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